Interleukin-19 in Breast Cancer
Inflammatory cytokines within the tumor microenvironment are linked to progression in breast cancer. Interleukin- (IL-) 19, part of the IL-10 family, contributes to a range of diseases and disorders, such as asthma, endotoxic shock, uremia, psoriasis, and rheumatoid arthritis. IL-19 is expressed in...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2013/294320 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849305640986476544 |
|---|---|
| author | Ying-Yin Chen Chien-Feng Li Ching-Hua Yeh Ming-Shi Chang Chung-Hsi Hsing |
| author_facet | Ying-Yin Chen Chien-Feng Li Ching-Hua Yeh Ming-Shi Chang Chung-Hsi Hsing |
| author_sort | Ying-Yin Chen |
| collection | DOAJ |
| description | Inflammatory cytokines within the tumor microenvironment are linked to progression in breast cancer. Interleukin- (IL-) 19, part of the IL-10 family, contributes to a range of diseases and disorders, such as asthma, endotoxic shock, uremia, psoriasis, and rheumatoid arthritis. IL-19 is expressed in several types of tumor cells, especially in squamous cell carcinoma of the skin, tongue, esophagus, and lung and invasive duct carcinoma of the breast. In breast cancer, IL-19 expression is correlated with increased mitotic figures, advanced tumor stage, higher metastasis, and poor survival. The mechanisms of IL-19 in breast cancer have recently been explored both in vitro and in vivo. IL-19 has an autocrine effect in breast cancer cells. It directly promotes proliferation and migration and indirectly provides a microenvironment for tumor progression, which suggests that IL-19 is a prognostic marker in breast cancer and that antagonizing IL-19 may have therapeutic potential. |
| format | Article |
| id | doaj-art-06f30df2f2eb4e25a94377784c85751e |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-06f30df2f2eb4e25a94377784c85751e2025-08-20T03:55:23ZengWileyClinical and Developmental Immunology1740-25221740-25302013-01-01201310.1155/2013/294320294320Interleukin-19 in Breast CancerYing-Yin Chen0Chien-Feng Li1Ching-Hua Yeh2Ming-Shi Chang3Chung-Hsi Hsing4Department of Medical Research, Chi-Mei Medical Center, Tainan 710, TaiwanDepartment of Pathology, Chi-Mei Medical Center, Tainan 710, TaiwanInstitute of Medical Science, College of Health Science, Chang Jung Christian University, Tainan 711, TaiwanInstitute of Biochemistry and Molecular Biology, Medical College, National Cheng Kung University, Tainan 701, TaiwanDepartment of Medical Research, Chi-Mei Medical Center, Tainan 710, TaiwanInflammatory cytokines within the tumor microenvironment are linked to progression in breast cancer. Interleukin- (IL-) 19, part of the IL-10 family, contributes to a range of diseases and disorders, such as asthma, endotoxic shock, uremia, psoriasis, and rheumatoid arthritis. IL-19 is expressed in several types of tumor cells, especially in squamous cell carcinoma of the skin, tongue, esophagus, and lung and invasive duct carcinoma of the breast. In breast cancer, IL-19 expression is correlated with increased mitotic figures, advanced tumor stage, higher metastasis, and poor survival. The mechanisms of IL-19 in breast cancer have recently been explored both in vitro and in vivo. IL-19 has an autocrine effect in breast cancer cells. It directly promotes proliferation and migration and indirectly provides a microenvironment for tumor progression, which suggests that IL-19 is a prognostic marker in breast cancer and that antagonizing IL-19 may have therapeutic potential.http://dx.doi.org/10.1155/2013/294320 |
| spellingShingle | Ying-Yin Chen Chien-Feng Li Ching-Hua Yeh Ming-Shi Chang Chung-Hsi Hsing Interleukin-19 in Breast Cancer Clinical and Developmental Immunology |
| title | Interleukin-19 in Breast Cancer |
| title_full | Interleukin-19 in Breast Cancer |
| title_fullStr | Interleukin-19 in Breast Cancer |
| title_full_unstemmed | Interleukin-19 in Breast Cancer |
| title_short | Interleukin-19 in Breast Cancer |
| title_sort | interleukin 19 in breast cancer |
| url | http://dx.doi.org/10.1155/2013/294320 |
| work_keys_str_mv | AT yingyinchen interleukin19inbreastcancer AT chienfengli interleukin19inbreastcancer AT chinghuayeh interleukin19inbreastcancer AT mingshichang interleukin19inbreastcancer AT chunghsihsing interleukin19inbreastcancer |